Stock Financial Ratios, Dividends, Split History

LDOS / Leidos Holdings, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price57.92
Volume1,625,300.00
Market Cap ($M)9,896.04
Enterprise Value ($M)11,651.68
Book Value ($M)3,431.00
Book Value / Share22.60
Price / Book2.99
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding 154,000,000
Preferred Stock Shares Outstanding 0
Weighted Average Number Of Shares Outstanding Basic 152,000,000
Common Shares Outstanding 151,459,401
Common Stock Shares Outstanding 151,000,000
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.06
Return on Assets (ROA)0.04
Return on Equity (ROE)0.12
Balance Sheet (mrq) ($M)
Assets8,913.00
Liabilities5,482.00
Quick Ration/a
Current Ratio1.25
Income Statement (mra) ($M)
Disposal Group Including Discontinued Operation Revenue0.00
Revenues10,170,000,000.00
Basis For Attributing Revenues From External Customers0.10
Operating Income559.00
Net Income364.00
Earnings Per Share Diluted2.38
Earnings Per Share Basic2.41
Cash Flow Statement (mra) ($M)
Cash From Operations526.00
Cash from Investing-71.00
Cash from Financing526.00
Identifiers and Descriptors
CUSIP525327102
Central Index Key (CIK)1336920
Related CUSIPS
525327902 78390X101 525327952

Split History

Stock splits are used by Leidos Holdings, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

9h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

9h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

7 Excellent Set-it-and-Forget-it ETFs for the Lazy Investor

2018-06-01 investorplace
To build long-term wealth for the big-ticket items and retirement, you need to invest. Keeping your money in a CD paying 2% won’t cut it. So, if you’re an investor seeking a set-it-and-forget-it exchange-traded fund (ETF) portfolio, then low-fee, diversified index funds are your solution. (383-0)

Here Are 23 Technology Safer Dividend WallStars For May

2018-05-30 seekingalpha
Top "safer" dividend Technology WallStar, Western Digital, showed 33.38% gains. All ten averaged 23.63% per Broker 1yr. Target gains plus dividends. Six leading gainers single-share prices exceeding dividends signaled oversold. (105-0)

The Zacks Analyst Blog Highlights: L3, Spirit AeroSystems, Leidos, Huntington Ingalls and Boeing

2018-05-10 zacks
Chicago, IL – May 10, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include L3 Technologies, Inc. (LLL - Free Report) , Spirit AeroSystems, Inc. (SPR - Free Report) , Leidos Holdings, Inc. (LDOS - Free Report) , Huntington Ingalls Industries, Inc. (26-0)

Defense Stock Roundup: LLL Tops, SPR & HII Lag Q1 Estimates, BA to Buy KLX

2018-05-09 zacks
With more than 409 S&P 500 companies having released their quarterly results, the Q1 earnings season is set to enter its last leg. As of May 4, of these 409 index members which revealed their earnings numbers, 78% delivered an earnings beat, while 75.6% surpassed revenue estimates. (12-0)

Top Analyst Upgrades and Downgrades: AGCO, American Water Works, Carbonite, Cheniere, Comcast, Northrup Grumman, Salesforce and More

2018-05-08 247wallst
Stocks were up on Monday but in Tuesday’s premarket were soft and looking for direction ahead of the president’s decision on the Iran nuke deal. The trend of endless buying the dips has not worked well lately, and many investors are wondering whether the best has been seen for 2018. Now investors have to consider how they want their investments positioned for the longer term. (182-0)

CUSIP: 525327102